Direct-to-Patient (DtP): The Future of Clinical Trials

Key Takeaways

• The Retention Revolution: Travel is the primary reason for a 30% patient dropout rate. Moving the clinical trial site to the home removes this barrier.
• ICH E6(R3) Readiness: Health regulators in Vietnam and across the region are preparing for the shift to updated standards in 2026. These rules require a Quality by Design approach.
• Unbroken Chain of Custody: Keeping unapproved medicines stable outside a clinic requires IoT sensors and white-glove delivery services.
• Scalable Compliance: Success across Asia-Pacific means navigating a complex system of medical licences and reaching participants in remote locations.

Traditional site-centric research models are running into barriers in 2026. Recruitment targets are frequently missed because patients cannot manage the time and travel required for hospital visits. We have built the DHL Health Logistics network to address this challenge directly. Our 2-billion-euro investment ensures you have the GDP-certified infrastructure and specialised handling needed to reach patients wherever they are. Direct-to-Patient (DtP) clinical trials bring the laboratory to the living room while maintaining the highest standards of safety.

Why is patient retention the biggest risk in 2026 clinical research?

Travel is the primary reason participants withdraw from clinical studies. When you move the trial site to the patient, you reduce missed visits and screen failures significantly.

• Travel Distance: Cancer trial patients travel a median of nearly 68 km for Phase I studies.
• Rural Hurdles: Participants in remote areas often travel more than 160 km each way.
• Human Connection: Technical couriers act as a professional extension of the clinical site, meeting participants at their front door.
• Supportive Experience: White-glove delivery services go beyond simple drop-offs to build genuine participant trust.

DHL Health Logistics provides the professional bridge between your laboratory and the participant. We understand that a courier is often the only face of the trial that a patient ever sees.

What are the 2026 regulatory requirements for DtP in Vietnam?

Regulators in Vietnam and neighbouring countries are rapidly updating their frameworks to support decentralised models. The new ICH E6(R3) guidelines require you to demonstrate that a medicine remained stable from the depot all the way to the patient's refrigerator.

• Transition Period: The latest ICH E6(R3) guidelines are expected to be adopted by health regulators globally throughout 2026, requiring sponsors to adapt to the new standards.
• Strict Accountability: Vietnam's Ministry of Health, through circulars such as Circular 29/2018/TT-BYT, requires rigorous temperature records and adherence to Good Clinical Practice (GCP).
• Thermal Protection: Advanced shippers maintain temperatures of 2 to 8°C or -20°C for up to 120 hours.
• Digital Proof: IoT sensors transmit live data to show precisely when a participant received the shipment.

Our investment in digital tools ensures you have a complete thermal audit trail. This level of transparency is a requirement for satisfying quality assurance teams in 2026.

How do you handle medical licence restrictions in emerging markets?

Delivering unapproved medicines to a private address is strictly regulated in countries such as Vietnam and its neighbours. You need a partner who understands the local Ministry of Health requirements.

• Health Reforms: Regulatory reforms are ongoing across Southeast Asia and directly affect how clinical materials can be transported.
• Fast-Track Routes: Some countries in the region are introducing new notification pathways for lower-risk trials.
• Expert Navigation: Our local specialists work with bodies such as the Ministry of Health (MOH) to keep your trial on track and compliant.
• Expanded Footprint: Having the right licences in place allows you to reach regions that were previously considered too complex to operate in.

Can you guarantee a secure chain of custody at the doorstep?

Security and privacy are critical when delivering sensitive products to a patient's home. You must ensure the medicine is handed directly to the verified participant or their legal representative.

• Identity Verification: We check identification documents against trial records before any package is handed over.
• Point-of-Use Delivery: Couriers place the medication directly into the participant's storage space or refrigerator.
• Instruction Support: We confirm the patient understands how to handle and store the packaging correctly.
• Safe Disposal: We collect used kits or sharps containers for disposal to medical-grade standards.

What is the role of reverse logistics in home-based trials?

A DtP trial does not end at the front door. You must also manage the return flow of biological samples and unused medicines back to the central laboratory.

• Stability Windows: Blood or urine samples must be collected and returned within strict time limits to remain viable.
• Data Integrity: If a sample warms during transit, the trial data it carries is compromised.
• Remote Reach: We use specialised transport, including road freight, to reach participants in rural or mountainous areas of Vietnam where infrastructure can be a challenge.
• Unified Visibility: A clinical research associate in Hanoi sees the same data as a sponsor in London.

Ready to streamline your clinical trial strategy?

Direct-to-Patient logistics is no longer a concept for the future. It is the most effective way to improve the patient experience and protect your data. DHL Health Logistics is ready to help you scale your research across the Asia-Pacific region. Speak to a DHL specialist today to review your trial plan and reach your participants with confidence.

Frequently Asked Questions